linjc16/ctgov huggingface dataset:
A Study to Evaluate the Efficacy and Safety of AD-203

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, active-controlled , randomized, double-blinded, paralleled group clinical study to evaluate the efficacy and safety of AD-203 to demonstrate the non-inferiority of AD-203 compared with Mucosta tab. in patients with acute or chronic gastritis

Official Title
-----------------
A Randomized, Double-blinded, Active Controlled, Non-Inferiority, Multicenter, Phase III Clinical Trial to Evaluate the Efficacy and Safety of AD-203 in Patients With Acute or Chronic Gastritis

Conditions
-----------------
Acute Gastritis, Chronic Gastritis

Intervention / Treatment
-----------------
* Drug: AD-203
* Drug: Mucosta tab.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age is over 20 years old, under 75 years old, men or women Patients diagnosed with acute or chronic gastritis by gastroscopy Exclusion Criteria: Patients who is impossible to receive gastroscopy Patients taking other investigational drugs or participating in other clinical studies in 3 months prior to screening visit

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AD-203<br> | Drug: AD-203<br>* AD-203 administered two times daily for two weeks<br>|
| Active Comparator: Mucosta tab.<br> | Drug: Mucosta tab.<br>* Mucosta tab. administered three times daily for two weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A percentage of subjects showed improvement of stomach erosions by the endoscopy. | Evaluate the improvement rate of Very much improved' and Much improved of subjects with stomach erosions. The definition of Very Much Improved is the subjects showed score changed from 4 to 1 or from 3 to 1. And, Much improved means the subject showed score changed from 4 to 2 or from 2 to 1. | 2 weeks |
Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers

Study Overview
=================
Brief Summary
-----------------
Find A Cure Panel is looking for people with Stage 4 stomach/gastric cancer or the caregivers of people with Stage 4 stomach/gastric cancer to participate in anonymous and qualitative research that will take an estimated 60 minutes of your time. This is opinion based, experiential research and is NOT a drug trial. Note that Stage IV is also known as advance disease or metastatic stomach/gastric cancer. If you are interested in participating, please email FACP at: info@findacurepanel.com

Official Title
-----------------
Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers

Conditions
-----------------
Stage 4 Stomach/Gastric Cancer, Patients and Caregivers

Intervention / Treatment
-----------------
* Behavioral: bulletin board and teleophone depth interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:stage 4 stomach cancer patients and caregivers - Exclusion Criteria:loved one must still be living -

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Qualitative Research<br>Experiential/opinion based research | Behavioral: bulletin board and teleophone depth interview<br>* qualitative based research<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage 4 stomach cancer, stage 4 gastric cancer
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

Study Overview
=================
Brief Summary
-----------------
The objective is to describe the safety profile after 1 dose of VaxigripTetra inj. administered in subjects aged 3 years old and above under routine clinical practice. The planned duration of each subject's participation in the study will be 21 to 28 days.

Official Title
-----------------
Postmarketing Surveillance Study for Use of Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) Administered Via the Intramuscular Route in Subjects Aged 3 Years Old and Above in the Republic of Korea

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Biological: VaxigripTetra inj.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 3 years and above on the day of enrollment For subjects aged 3 to 18 years: Informed consent form has been signed and dated by the parent or other legally acceptable representative. For subjects 19 years and above: Informed consent form has been signed and dated by the subject. Receipt of one dose of VaxigripTetra inj. (on the day of inclusion) as part of routine clinical practice according to the approved local product insert Exclusion Criteria: - Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device, or medical procedure

Ages Eligible for Study
-----------------
Minimum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: VaxigripTetra inj.|Suspension for injection in a pre-filled syringe Injection intramuscular|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with solicited injection site or systemic reactions | Percentage of participants reporting injection site reactions: pain, erythema, swelling, induration, ecchymosis systemic reactions: fever, headache, malaise, myalgia, shivering | Up to 7 days after vaccination | 
| Number of participants with unsolicited adverse events | Percentage of participants with unsolicited (spontaneously reported) injection site reactions occurring within 28 days after each injection and unsolicited systemic AEs between each injection and up to 28 days after the last injection | Up to Day 28 | 
| Number of participants with serious adverse events (SAEs) | Percentage of participants with SAEs, including AESIs, throughout the study | Up to Day 28 |
Effects of Liothyronine on Energy Expenditure and Cardiovascular Function

Study Overview
=================
Brief Summary
-----------------
This study will assess the short term effects of a single dose of liothyronine on the cardiovascular system and energy expenditure

Official Title
-----------------
Effects of Liothyronine on Energy Expenditure and Cardiovascular Function

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Liothyronine
* Drug: Levothyroxine
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI >20<30 kg/m2 TSH >0.5<5.0 mcIU/mL Negative TPO antibodies Exclusion Criteria: Pregnancy Use of prescription drugs Diabetes mellitus Coronary artery disease Hypertension Anemia Renal insufficiency Liver disease or ALT >2.5 x the upper laboratory reference limit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: double blind, crossover
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Liothyronine<br>Each participant will receive a single dose of lithyronine | Drug: Liothyronine<br>* Single dose<br>|
| Active Comparator: Levothyroxine<br>Each participant will receive a single dose of levothyroxine | Drug: Levothyroxine<br>* Active comparator<br>|
| Placebo Comparator: Placebo<br>Each participant will receive a single dose of placebo | Drug: Placebos<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiac Output | Cardiac output measured by Echocaridogram, Difference in Stroke Volume Pre- and Post- Drug Administration | five hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy Expenditure | Energy expenditure measured by Whole-Room Indirect Calorimeter, Difference in energy Expenditure Pre- and Post- Drug Administration Kcal | five hours |
Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis

Study Overview
=================
Brief Summary
-----------------
Disorders of glucose metabolism, such as impaired glucose intolerance (IGT) and diabetes mellitus (DM), frequently occur in cirrhosis. However, it has been underestimated when fasting plasma glucose (FPG) levels are considered. We aimed to evaluate who needs to be undertaken a 75-g oral glucose tolerance test (OGTT) to find underlying subclinical diabetes.

Official Title
-----------------
Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis

Conditions
-----------------
Liver Cirrhosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Liver cirrhosis Admitted to a hospital Exclusion Criteria: Previously confirmed DM Being treated for DM Standard risk factors of T2DM, such as high body mass index and family history of diabetes Symptoms of DM, such as increased thirst and the need to urinate Either hepatocellular carcinoma or other malignancy Hepatic failure or uncontrolled decompensation [that is, refractory ascites or active variceal hemorrhage] Significant illnesses such as sepsis that may have interfered with glucose metabolism Pancreatic dysfunction such as acute/chronic pancreatitis that may have affected glucose metabolism.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| normal glucose tolerance (NGT)<br>In the 75-g OGTT, an FPG level of < 100 mg/dL or a 120-min PG level of < 140 was diagnosed as NGT. | |
| impaired glucose intolerance (IGT)<br>In the 75-g OGTT, an FPG level of 100-125 mg/dL (5.6-6.9 mmol/L) or a 120-min PG level of 140-200 mg/dL (7.8-11.1 mmol/L) was diagnosed as IGT. | |
| newly diagnosed DM (subclinical DM)<br>In the 75-g OGTT, a basal FPG level ˃126 mg/dL (7.0 mmol/L) or a 120-min PG level ˃200 mg/dL (11.1 mmol/L) was considered as newly diagnosed DM (hereafter referred to as subclinical DM). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | Overall survival | through study completion, an average of 3 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| major complications of cirrhosis | hepatic encephalopathy (HE), the development of spontaneous bacterial peritonitis (SBP), acute kidney injury (AKI), variceal bleeding, and infection | through study completion, an average of 3 year |
Motec Versus Remotion Total Wrist Arthroplasty - A Prospective Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the difference in the results between Motec and Remotion wrist arthroplasty in the treatment of non-rheumatoid wrist arthritis.

Official Title
-----------------
Motec Versus Remotion Total Wrist Arthroplasty - A Prospective Randomized Study.

Conditions
-----------------
Non-rheumatoid Wrist Arthritis

Intervention / Treatment
-----------------
* Procedure: Motec total wrist arthroplasty
* Procedure: Remotion total wrist arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with painful non-rheumatoid wrist arthritis (posttraumatic arthritis and late stage Kienboeck's disease) Age 18-70 years ASA class 1-3

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Motec total wrist arthroplasty<br> | Procedure: Motec total wrist arthroplasty<br> <br> |
| Active Comparator: Remotion total wrist arthroplasty<br> | Procedure: Remotion total wrist arthroplasty<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PRWHE (Patient rated Wrist and Hand Evaluation score) | PRWHE is a wrist specific patient assessed questionnaire, measuring pain, wrist specific function and general function | 24 months postop | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wrist movement | Overall degree of flexion, extension, radial and ulnar deviation | 24 months postop | 
| Grip Strength |  | 24 months postop | 
| Pain in affected wrist | Visual analogue scale | 24 months postop | 
| Quick-DASH | Disabilities of the Arm, Shoulder and Hand questionnaire | 24 months postop | 
| intraoperative complications |  | intraoperative | 
| Postoperative complications |  | 24 months postop | 
| Implant loosening | Implant loosening seen on x-ray | 24 months postop | 
| Implant migration | Implant migration seen on model-based roentgen stereophotogrammetric analysis (RSA), as a possible precursor of later implant loosening | 24 months postop | 
| Periprosthetic bone mineral density | BMD measured with DEXA (dual-energy x-ray absorptiometry) | 24 months postop | 
| Reoperations | Reoperations of any cause | 24 months postop |
Evaluation of the Influence of Output on Skin Covered by Adhesives

Study Overview
=================
Brief Summary
-----------------
The study investigates the impact real output has on peristomal skin covered by two different adhesives

Conditions
-----------------
Ileostomy - Stoma

Intervention / Treatment
-----------------
* Other: standard adhesive
* Other: New adhesive strip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have given written informed consent Be at least 18 years of age and have full legal capacity Have had an ileostomy for more than one year Have intact skin on the area used in the evaluation Has an ileostomy with a diameter up to 35 mm Have a peristomal area accessible for application of adhesive strips Exclusion Criteria: Currently receiving or have within the past 2 month received radio- and/or chemotherapy Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment. Are pregnant or breastfeeding Having dermatological problems in the peristomal- or abdominal area (assessed by investigating scientist) Participating in other interventional clinical investigations or have previously participated in this evaluation -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 6<br>This is a sub-study testing the effect of real output applied under two adhesive strips after 8 hours. | Other: standard adhesive<br>* This is a standard adhesive (hydrocolloid)<br>Other: New adhesive strip<br>* This is a newly developed adhesive strip<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Trans Epidermal Water Loss |  | 8 hours |
Doppler Ultrasound in Rewarming After Targeted Control Management in Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to describe CBF modifications during rewarming after targeted temperature management in cardiac arrest patients

Conditions
-----------------
Cardiac Arrest, Doppler Ultrasound

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major Cardiac arrest Targeted temperature management Exclusion Criteria: GCS>8 after cardiac arrest Neurologic cause of cardiac arrest

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in TCD estimates of CBF measurements |  | day 3 |
Anatomy and Ultrasound Evaluation for Central Venous Access

Study Overview
=================
Brief Summary
-----------------
The anatomy and ultrasound image of subclavian vein was investigated on cadavers, volunteers and patients, respectively. Structures，approach，position and complications were discussed to improve the success rate and safety of central venous catheterization.

Official Title
-----------------
Optimisation of Subclavian Venous Catheterization

Conditions
-----------------
Catheterization, Central Venous; Ultrasonography

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-65 years old gender unlimited 18.5 < body mass index (BMI) < 30 written consent signed. Exclusion Criteria: abnormality of the infraclavicular region, including infection, deformity, history of bone, joint, muscle or neurovascular disease history of injury, radiation or invasive procedure subjects refused.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neutral<br> | |
| abduction<br> | |
| pad<br> | |
| combination<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| area | SV area in square centimeter | 12 months | 
| length | SV length in centimeter | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| width | SV width in centimeter | 12 months | 
| skin distance | depth from skin in centimeter | 12 months | 
| comfort | comfort level rated by Likert scale ranged point 1 to 5, indicating increased comfort level | 12 months |
White Coat Hypertension and Antihypertensive Treatment Effect - SCOR in Hypertension

Study Overview
=================
Brief Summary
-----------------
To investigate the mechanisms of white coat hypertension and study it further as a risk factor for heart damage.

Detailed Description
-----------------
BACKGROUND: The multidisciplinary SCOR examined causes, consequences, and treatments of human hypertension. A central theme was the renal basis for human hypertension. The subproject on white coat hypertension began in December of 1985. DESIGN NARRATIVE: In the longitudinal study, eighty patients with white coat hypertension were compared with 40 age- and sex-matched normotensives, and with 80 patients with sustained hypertension. The protocol consisted of (a) clinic blood pressure measurements made both by a physician and a nurse, (b) self-monitoring at home, (c) noninvasive ambulatory monitoring, (d) reactivity testing (cold pressor test, mental arithmetic, and isometric exercise) and (e) Korotkoff signal recording. Patients were also tested for early markers of disease (echocardiography and urine albumin). The 80 patients in each of the two hypertensive groups were randomized to one of four treatment protocols (20 patients each); an alpha blocker, a beta blocker, a combined alpha- and beta-blocker, or an ACE inhibitor. The doses of medication were adjusted to produce similar reductions of clinic blood pressure in the different groups. The test battery (a-e) was reported during treatment. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |